SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
December 18, 2001
Interneuron Pharmaceuticals, Inc.
---------------------------------
(Exact name of registrant as specified in its charter)
Delaware 000-18728 04-3047911
---------------- ------------- ----------------
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification
incorporation) Number)
One Ledgemont Center
99 Hayden Avenue
Lexington, Ma 02421-7966
--------------------------------------------
(Address of principal executive offices)
Registrant's telephone number, including area code:
(781-861-8444)
ITEM 5. Other Items.
------- ------------
On December 18, 2001, Interneuron Pharmaceuticals, Inc. (the "Company")
issued a press release containing the information attached hereto as Exhibit
99.1 announcing that Pfizer Inc. reported positive clinical trial results in
generalized anxiety disorder with the Company's product pagoclone. The Company
also reported on the progress of other clinical-stage products. The press
release is incorporated herein by reference.
The press release contains forward-looking statements that involve risks
and uncertainties that could cause our actual results and financial condition to
differ materially from those anticipated by the forward-looking statements. The
words "believe", "expect", "anticipate", "intend", "plan", "estimate" or other
expressions which are predictions of or indicate future events and trends do not
relate to historical matters but identify forward-looking statements. Risks and
uncertainties related to forward-looking statements are set forth in the
Company's filings under the Securities Act of 1933 and the Securities Exchange
Act of 1934 under "Risk Factors" and elsewhere in, or incorporated by reference
into, the Company's Form 10-K for its fiscal year ended September 30, 2001 and
elsewhere.
Item 7. Financial Statements and Exhibits.
------- ----------------------------------
(a) Financial Statements of Business Acquired: N/A
(b) Pro Forma Financial Information: N/A
(c) Exhibits: Exhibit 99.1 Press Release dated December 18, 2001
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
INTERNEURON PHARMACEUTICALS, INC.
Dated: December 20, 2001 By: /s/ Glenn L. Cooper, M.D.
-------------------------
Glenn L. Cooper, M.D.
President, Chief Executive Officer
and Chairman
-2-